PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
 
J Clin Invest. 2007 August 1; 117(8): 2095–2104.
Published online 2007 August 1. doi:  10.1172/JCI32022
PMCID: PMC1934589

Proteolytic processing of dynamin by cytoplasmic cathepsin L is a mechanism for proteinuric kidney disease

Abstract

Kidney podocytes and their foot processes maintain the ultrafiltration barrier and prevent urinary protein loss (proteinuria). Here we show that the GTPase dynamin is essential for podocyte function. During proteinuric kidney disease, induction of cytoplasmic cathepsin L leads to cleavage of dynamin at an evolutionary conserved site, resulting in reorganization of the podocyte actin cytoskeleton and proteinuria. Dynamin mutants that lack the cathepsin L site, or render the cathepsin L site inaccessible through dynamin self-assembly, are resistant to cathepsin L cleavage. When delivered into mice, these mutants restored podocyte function and resolve proteinuria. Our study identifies dynamin as a critical regulator of renal permselectivity that is specifically targeted by proteolysis under pathological conditions.

Introduction

In the US alone, kidney diseases affect some 20 million people, twice as many as it did 2 decades ago. Renal ultrafiltration occurs in glomeruli, specialized structures that ensure permselectivity of the kidney filter so that essential plasma proteins are retained in the blood. A sign of glomerular dysfunction is the loss of protein in the urine (termed proteinuria or nephrotic syndrome if protein loss exceeds 3.5 g/d). Proteinuria often leads to progressive renal failure, eventually requiring dialysis or kidney transplantation (1). Podocytes are specialized cells within the glomerulus that are essential for ultrafiltration (Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI32022DS1). Podocytes form foot processes (FPs), highly dynamic cellular extensions that are connected by slit diaphragms. Together with the glomerular basement membrane (GBM) and the glomerular endothelial cells, podocytes form a key component of the kidney permeability barrier. Most forms of proteinuria are characterized by a reduction of podocyte membrane extensions in number and size as well as transformation of podocyte FPs into a band of cytoplasm (referred to as FP effacement). Familial mutations underlie only a small percentage of kidney diseases (2) and therefore do not readily explain the molecular mechanisms underlying the far more common acquired causes of FP effacement and proteinuria. In this study, we show that dynamin is essential to maintain the filtration barrier in kidneys due to a role in regulating actin dynamics in podocytes. We further demonstrate that CatL is responsible for FP effacement. CatL affects podocyte function by cleaving dynamin in the cytoplasm. The cleavage of dynamin by CatL is inhibited when dynamin is induced to self-assemble. Gene delivery of dynamin mutants that are prone to self-assemble into higher-order structures, or that contain a mutated CatL cleavage site, can prevent and reverse podocyte FP effacement and proteinuria in a mouse model of proteinuria.

Results

Cathepsin L is necessary for podocyte FP effacement and proteinuria in a mouse model.

Cathepsin L (CatL) belongs to a subclass of cysteine proteases termed lysosomal cathepsins, which are involved primarily in protein breakdown within the lysosomal compartment. Interestingly, CatL is strongly induced in rodent nephrotic podocytes (3). Moreover, earlier studies showed that inhibitors of cysteine proteases reduced proteinuria in rats, possibly by inhibiting degradation of the GBM (4). Recently, Goulet and colleagues described a novel role for CatL in processing of the CDP/Cux transcription factor in the nucleus during the S phase (5). Together, these findings raise many possibilities for the potential site of CatL action during the pathogenesis of proteinuria, including the cytoplasm. To explore the relevance of CatL in human kidney disease, we examined CatL mRNA levels using quantitative real-time PCR (rt-PCR) in microdissected glomeruli from patients with acquired proteinuric diseases (6). CatL mRNA levels were 2-fold or greater in biopsy samples from patients with 3 types of proteinuric kidney diseases — membranous glomerulonephritis, focal segmental glomerulosclerosis, and diabetic nephropathy — compared with control samples (Figure (Figure1A).1A). Samples from patients with minimal change disease, which is characterized by reversible podocyte FP effacement, showed only a minor increase. There was also a significant increase in staining for CatL in glomeruli of patients with diabetic nephropathy (in Figure Figure1,1, compare B and C). The glomerulus contains 4 major cell types: podocytes, endothelial cells, mesangial cells, and cells of the Bowman capsule. CatL was induced in the nuclei of glomerular cells, in line with its role in cleaving transcription factors (5). There was also a strong increase in CatL within cells of the Bowman capsule (Figure (Figure1C,1C, arrowheads) and proximal tubular cells as shown before in proteinuric states (Figure (Figure1C,1C, asterisk; ref. 7). Finally, CatL staining was also elevated in the cytoplasm of podocytes (Figure (Figure1C,1C, red arrows).

Figure 1
CatL is essential for proteinuric kidney diseases.

We next examined whether a similar upregulation of CatL occurs in the LPS mouse model of proteinuria (3). Immunocytochemistry using anti-CatL antibodies (8, 9) detected weak CatL staining in normal glomeruli (Figure (Figure1D,1D, left). Glomerular CatL labeling increased within 24 hours after a single LPS injection (Figure (Figure1D,1D, middle) but not in mice lacking CatL (Figure (Figure1D,1D, right) (10). LPS treatment resulted in FP effacement in control mice (Figure (Figure1E,1E, left and middle) but not in the LPS-treated CatL–/– mice (Figure (Figure1E,1E, right). Finally, urinary protein increased from a baseline level of approximately 0.25 mg/ml to 1.2 ± 0.15 mg/ml in control mice but remained unchanged in LPS-treated CatL–/– mice (0.25 ± 0.11 mg/ml) (Figure (Figure1F).1F). These data provide genetic evidence that CatL is essential for proteinuria.

LPS induces expression of cytoplasmic CatL.

To investigate how CatL triggers proteinuria, we examined its subcellular activity before and after LPS treatment in cultured podocytes. Subcellular sites of CatL and CatB activity were visualized by a fluorogenic substrate, CV-(FR)2, which emits light upon cleavage by CatL or CatB (3). In untreated podocytes, protease activities were restricted to lysosomes (Figure (Figure2A,2A, left column). LPS treatment dramatically increased protease activity, which now extended outside lysosomes into the cytoplasm (Figure (Figure2A,2A, middle column). The vast majority of cytoplasmic cathepsin activity after LPS administration could be attributed to CatL, since it was sensitive to the CatL inhibitor Z-FF-FMK, which does not inhibit CatB (Figure (Figure2A,2A, right column; notice only perinuclear red staining). In line with the CatL activity in the cytoplasm, CatL protein colocalized with the lysosome-associated membrane protein LAMP-2 in lysosomes of control cells (Figure (Figure2B,2B, left column). After LPS treatment, there was a dramatic increase in overall CatL staining, some of which was present in the cytosol as well as in the nucleus (Figure (Figure2B,2B, right column). In addition, induced CatL was detected in LAMP-2–positive vesicles extending in podocyte processes close to the plasma membrane, which likely represent vesicles targeted for secretion (Supplemental Figure 1B and ref. 9). The relocalization of CatL upon LPS treatment was specific, since other lysosomal proteases such as CatB (Figure (Figure2C)2C) and mannosidase α (Supplemental Figure 1C) colocalized exclusively with LAMP-2 before and after LPS treatment. Finally, the presence of CatL in the cytoplasm was not due to lysosomal leakage (Supplemental Figure 1D).

Figure 2
Induction of cytoplasmic CatL protein and activity by LPS.

The mRNA for CatL contains several AUG codons (Figure (Figure2D).2D). After translation from the first AUG, CatL is processed to yield a 30-kDa lysosomal form, called single-chain CatL (Figure (Figure2D,2D, black arrows). However, alternative translation initiation from a downstream AUG produces a CatL isoform devoid of the lysosomal targeting sequence (called short CatL), which localizes to the cytoplasm (Figure (Figure2D,2D, red arrow; ref. 5). To test whether LPS induces expression of short CatL, subcellular fractionation experiments using cultured podocytes were performed. The particulate fraction contains membranes, including lysosomes, whereas the soluble fraction represents cytoplasm. GAPDH was used as a marker for soluble cytosolic proteins and the efficiency of lysis. As expected, lysosomal single-chain CatL (30 kDa) was present in the particulate fraction, which also contained LAMP-2, CatB, and mannosidase α (Figure (Figure2E,2E, lane 2). LPS treatment for 24 hours led to strong induction of a 34-kDa short CatL, which was present exclusively in the cytoplasm (Figure (Figure2E,2E, compare lanes 1 and 3). In contrast, there was no significant increase in the amount of the single-chain form, LAMP-2, or mannosidase α (Figure (Figure2E,2E, lanes 2 and 4). In addition, the soluble fractions were not contaminated with nuclear proteins such as the transcription factor Wilms tumor 1 (Supplemental Figure 1E), indicating that the soluble short form of CatL did not come from the nuclear compartment. Interestingly, addition of LPS also induced expression of the 39-kDa pro-CatL, which is known to be secreted (Figure (Figure2E2E and Supplemental Figure 1B). The ability of CatL mRNA to allow downstream AUG translation and thus generate cytoplasmic CatL was confirmed by transfecting CatL–/– fibroblasts with a cDNA in which the first AUG codon had been mutagenized (Supplemental Figure 1, F and G; ref. 5).

Loss of dynamin staining in podocytes correlates with the proteinuria and is CatL dependent.

We next attempted to identify a target of cytoplasmic CatL. The computer-based algorithm PEPS (Prediction of Endopeptidase Substrates; ref. 11) identified the GTPase dynamin as a potential CatL substrate (data not shown). Dynamin is a large GTPase essential for the formation of clathrin-coated vesicles at the plasma membrane (12), and it has also been implicated in the regulation of actin dynamics in certain cell types (13). We first examined dynamin distribution in podocytes using immunogold EM. Dynamin antigenic sites were detected within the center of podocyte FPs (Figure (Figure3A,3A, left, asterisk) and in electron-dense areas rich in cortical actin cytoskeleton (Figure (Figure3A,3A, left, a). In addition, a high-power view localized dynamin on the cytoplasmic side of vesicular structures, which are most likely clathrin-coated pits (Figure (Figure3A,3A, right, v). Next, we examined dynamin staining in mice before and after LPS treatment. As expected based on the EM data, immunocytochemistry in control mice detected dynamin staining in glomeruli (Figure (Figure3B,3B, left), in a pattern consistent with podocyte expression. Twenty-four hours after a single LPS injection, dynamin labeling in the glomerulus appeared weaker and clustered (Figure (Figure3B,3B, middle panel), but it remained unchanged in tubules (data not shown). A similar dynamin staining pattern was observed in a rat model for proteinuric kidney disease in which animals are injected with puromycin aminonucleoside (PAN) (Supplemental Figure 2A; ref. 14), suggesting that changes in glomerular dynamin staining are associated with proteinuria. Importantly, dynamin staining was preserved in CatL–/– mice treated with LPS (Figure (Figure3B,3B, right). We hypothesize that the alteration of dynamin staining in vivo is due to proteolysis by cytoplasmic CatL. To investigate this possibility, DNAs encoding for short-form CatL or pre-pro-CatL were injected in CatL–/– mice using transient gene delivery (15, 16). Both DNA constructs led to glomerular CatL expression (Figure (Figure3C,3C, top row). Strikingly, expression of the short CatL specifically altered dynamin staining in a manner similar to that seen with LPS (Figure (Figure3C,3C, bottom row). Together with the fact that dynamin is a substrate of CatL in vitro (see below), these data are consistent with dynamin being cleaved by CatL in kidney after LPS treatment. Because isolated glomeruli from animals also contain other resident cells, we quantified dynamin abundance before and after LPS treatment using cultured podocytes. Western blotting of podocyte lysates revealed an approximately 30% decrease in the amount of endogenous dynamin after LPS treatment (Figure (Figure3,3, D and E). Dynamin reduction was CatL dependent, since it did not occur when CatL was downregulated using siRNA (Figure (Figure3D3D and Supplemental Figure 2, B and C). Together, these data suggest that the cytoplasmic CatL targets dynamin in rodent models of proteinuria.

Figure 3
Altered dynamin staining in glomerulus after LPS treatment is CatL dependent.

CatL cleaves dynamin:GTP in vitro and in vivo.

If dynamin is a CatL target in the cytoplasm, then recombinant dynamin should be cleavable by CatL at neutral pH. The PEPS algorithm identified a potential recognition sequence (ELSGGA) within dynamin between amino acids 354 and 359. Interestingly, the ELSGGA motif is highly conserved among several species (Figure (Figure4A).4A). CatL did not cause significant cleavage of dynamin at pH 7.0 (Figure (Figure4C,4C, compare lanes 1 and 2). Strikingly, addition of GTP resulted in the generation of a prominent proteolytic fragment with a molecular weight of approximately 40 kDa (p40) (Figure (Figure4C,4C, lane 3). p40 is the predicted size of the N-terminal fragment after cleavage at the ELSGGA sequence (Figure (Figure4A).4A). Another fragment, p55, is observed in the absence of added protease (Figure (Figure4C,4C, lane 1). Thus, p55 is not a precursor of p40. Furthermore, incubation of dynamin with CatB generated p55 in a nucleotide-independent manner (Figure (Figure4C,4C, lanes 5–8), whereas the protease furin was unable to cleave dynamin (Figure (Figure4C,4C, lanes 9–12). Thus, while p55 is produced by a number of proteases and thus represents a “hot spot” for proteolysis (17), p40 is generated by CatL only when dynamin is in the GTP-bound conformation. Interestingly, addition of GTP[Upsilon]S (nonhydrolyzable GTP analog) did not stimulate cleavage by CatL (Figure (Figure4C,4C, lane 4). These data can be explained in terms of dynamin’s oligomerization status. In its basal state, dynamin is a homotetramer that can self-associate into rings or spirals when bound to GTP (Figure (Figure4B).4B). These higher-order dynamin structures exhibit elevated GTPase activity, which in turn drives their disassembly. GTP[Upsilon]S stabilizes oligomerized dynamin due to inhibition of GTP hydrolysis (18). Dynamin oligomerization is mediated by the middle and GAP domains of dynamin (19), and based on a cryo-EM reconstruction of assembled dynamin (20), amino acids ELSGGA (located in the middle domain) are predicted to be inaccessible when dynamin is self-assembled (Figure (Figure4B).4B). To test the idea that dynamin self-assembly protects against CatL cleavage, we performed additional cleavage experiments at an acidic pH where CatL is more active. At pH 5.0 and 6.0, CatL was highly reactive toward recombinant dynamin, even in the absence of GTP (Figure (Figure4D,4D, lanes 2 and 4). Strikingly, this proteolysis was inhibited by addition of GTP[Upsilon]S (Figure (Figure4D,4D, lanes 3 and 5). Together, our data are consistent with the hypothesis that the primary site recognized by CatL is within a domain that becomes inaccessible upon dynamin self-assembly.

Figure 4
Effects of the nucleotide-bound and assembly state of dynamin on CatL cleavage in vitro and in vivo.

To further explore CatL-mediated dynamin cleavage, we infected cultured podocytes with adenoviruses encoding different dynamin mutants (Figure (Figure4A)4A) and subsequently treated them with LPS. As expected, addition of LPS to cells expressing dynWT resulted in generation of p40 (Figure (Figure4E,4E, lane 6), which was inhibited by the addition of the CatL inhibitor Z-FF-FMK (Figure (Figure4E,4E, lane 5). Importantly, LPS treatment of podocytes expressing dynK44A (a mutant that cannot bind GTP) did not result in detectable levels of p40 (Figure (Figure4E,4E, lane 7), consistent with our data that in vitro cleavage of dynamin by CatL at neutral pH is GTP dependent. To confirm the identity of the cleavage site, we created dynL356Q, in which the ELSGGA sequence was mutated to EQSVGA. The addition of LPS to cultured podocytes overexpressing dynL356Q yielded no p40 (Figure (Figure4E,4E, lane 9). Finally, we examined a GTPase-defective dynamin mutant carrying a mutation in its GAP domain (dynR725A). This mutant dynamin oligomerizes, but is impaired in assembly-stimulated GTP hydrolysis (Figure (Figure4B;4B; ref. 19). dynR725A is therefore predicted to live longer in the assembled state. Consistent with our model, LPS treatment of cells expressing dynR725A did not generate p40 (Figure (Figure4E,4E, lane 8). To demonstrate that dynamin cleavage by CatL occurred in the cytoplasm, we performed subcellular fractionation experiments. Thus, the N-terminal p40 was detected only in the supernatant fraction (Figure (Figure4F,4F, left lane, GTPase), whereas the C-terminal part of dynamin was found degraded in the pellet fraction (Figure (Figure4F,4F, right lane, GAP). Together, these data support a model in which CatL specifically targets the GTP-bound form of dynamin in the cytoplasm by recognizing an evolutionally conserved ELSGGA motif and that dynamin self-assembly into higher-order structures such as rings or spirals prevents CatL cleavage.

To demonstrate that dynamin is cleaved by cytoplasmic CatL during proteinuric kidney disease, we looked for p40 in mouse kidney extracts after LPS treatment. Since the GTPase antibody, which recognizes p40, was not sufficiently sensitive to detect endogenous dynamin cleavage fragments (data not shown), we used a gene-delivery protocol to express dynamin in mouse kidneys (15, 16). We delivered dyn1 because overexpression of dyn2 sometimes induces apoptosis (21). rt-PCR showed that podocytes normally express dyn2 (ubiquitous form) and some dyn3 (predominantly expressed in testis), but no dyn1 (neuronal isoform; Supplemental Figure 3A). Dyn1 was expressed from a CMV promoter (CMV-dyn) or from the podocyte-specific podocin promoter (POD-dyn; ref. 22). Gene-delivered dyn1 was distinguished from endogenous dyn2 using the monoclonal dynamin antibody MAB-5402, which predominantly recognizes dyn1 (Supplemental Figure 3B). As expected, MAB-5402 weakly stained control glomeruli (Figure (Figure5A),5A), whereas it strongly stained glomeruli 14 hours after delivery of CMV-dyn1 (Figure (Figure5B)5B) or POD-dyn1 (Figure (Figure5C).5C). The CMV promoter directed expression of dyn1 in the liver and kidney (Figure (Figure5B,5B, Western blot), and dyn1 was detected in virtually all resident cell types of the glomerulus including podocytes, as seen from colocalization with synaptopodin (Figure (Figure5B,5B, Merge). In contrast, the podocin promoter directed expression exclusively in the kidney (Figure (Figure5C,5C, Western blot), and dyn1 localized predominantly in podocytes (Figure (Figure5C,5C, Merge). The presence of dyn1 in FPs of podocytes was demonstrated using EM (Supplemental Figure 3C). Importantly, LPS treatment led to altered staining of gene-delivered dyn1WT in glomeruli, whereas the staining of dynL356Q and dynR725A remained unchanged (Figure (Figure5D).5D). Moreover, LPS treatment resulted in generation of p40, but only in mice expressing dynWT (Figure (Figure5E,5E, lane 2) and not in mice expressing dynL356Q and dynR725A (Figure (Figure5E,5E, lanes 4 and 6). Generation of p40 required the presence of CatL, since it was not detected in CatL–/– mice injected with LPS (Supplemental Figure 3D). Western blotting also detected a dynamin fragment of approximately 55 kDa. As in cultured podocytes, the presence of this fragment was LPS and CatL independent (Figure (Figure5E,5E, lanes 3 and 5, and Supplemental Figure 3D), supporting the idea that it is generated by other proteases during extract preparation. These experiments extend our observations in the cultured podocytes and indicate that LPS induces CatL-dependent cleavage in live mice.

Figure 5
LPS-induced dynamin cleavage in mouse kidneys.

Dynamin is required for normal glomerular function.

The hypothesis that cleavage of dynamin by CatL leads to proteinuria implies that dynamin is essential for podocyte morphology in healthy kidneys. In support of this notion, expression of dominant-negative dynK44A in mouse podocytes caused severe proteinuria (Figure (Figure6A6A and Supplemental Table 1) and FP effacement (Supplemental Figure 4B, 14 hours). Proteinuria and FP effacement were maximum 14 hours after gene delivery and returned to baseline after loss of dynK44A expression (Supplemental Figure 4, A and B, and data not shown). Expression of dynWT did not cause changes in FP architecture (data not shown) or significant proteinuria (Figure (Figure6A6A and Supplemental Table 1), demonstrating specificity of the dynK44A phenotype. Importantly, expression of p40 also caused proteinuria (Figure (Figure6A6A and Supplemental Table 1), demonstrating that this dynamin fragment has dominant-negative characteristics with respect to podocyte function.

Figure 6
The effects of dynamin mutants on proteinuria and podocyte morphology.

Since podocyte FP effacement is primarily driven by the rearrangement of the actin cytoskeleton (23), we examined actin morphology in cultured podocytes expressing dynK44A and p40. Podocytes were infected using an adenoviral expression system, which allows greater than 90% infection efficiency (24). The experiments were performed using the neuronal isoform of dyn1 (Figure (Figure6B)6B) as well as the ubiquitously expressed dyn2 (Supplemental Figure 5). The 2 isoforms yielded identical results, demonstrating that the observed phenotypes in podocytes were not isoform specific (compare F-actin staining in cells expressing dynWT and dynK44A in Figure Figure6B6B and Supplemental Figure 5). Podocyte actin is organized in parallel bundles of stress fibers and a cortical ring of filamentous actin (Figure (Figure6B,6B, CON). Expression of dynWT did not significantly alter the F-actin staining pattern (Figure (Figure6B,6B, WT). In contrast, the expression of dynK44A or p40 abolished stress fibers while enhancing the cortical actin web, resulting in a polygonal cellular shape (Figure (Figure6B).6B). Similar actin and cell morphology phenotypes were associated with LPS (Figure (Figure6B)6B) and PAN treatments (25). Thus, occurrence of proteinuria in mice expressing dynK44A or p40 (Figure (Figure6A)6A) correlates with changes in podocyte morphology due to changes in actin cytoskeleton (Figure (Figure6B). 6B).

If dynamin is a target of CatL, then dynL356Q and dynR725A, which are resistant to CatL cleavage, might be beneficial during LPS-induced proteinuria. At peak proteinuria (48 hours after initial LPS), mice were injected with empty vector, dynWT, dynL356Q, or dynR725A either from the CMV promoter (Figure (Figure6C)6C) or the podocin promoter (Figure (Figure6D),6D), and the degree of proteinuria was analyzed 12 hours after DNA injection. Strikingly, expression of dynR725A led to almost complete resolution of proteinuria, whereas expression of dynL356Q reduced proteinuria by approximately 50% (Figure (Figure6,6, C and D; 60-hour time point). Interestingly, while CMV-dynWT had no affect on proteinuria (Figure (Figure6C),6C), podocin-driven expression reduced proteinuria by 50% (Figure (Figure6D).6D). The ability of POD-dynWT to overcome proteinuria is likely due to the higher level of podocyte-specific dynamin expression expected from the podocin promoter. Indeed, kidney extracts from animals expressing POD-dynWT contained the same level of dynamin as extracts from animals expressing CMV-dynWT, even though the latter was expressed in all cell types in the glomerulus (Figure (Figure5,5, B and C). Thus, while expression of a high level of dynWT can partially reverse LPS-induced FP effacement, dynL356Q and dynR725A are more potent. Interestingly, dynR725A is the most powerful, most likely due to restoration of optimal cellular levels of dynamin:GTP.

Discussion

In this study, we investigated the role of the protease CatL and the large GTPase dynamin in healthy and diseased kidney podocytes. We show that dynamin is normally required to maintain the ultrafiltration barrier in kidneys, possibly via regulation of the actin cytoskeleton in podocytes. Using a mouse model for inducible kidney failure, we found that cleavage of dynamin by a cytoplasmic form of CatL leads to podocyte failure and proteinuria. Gene delivery of CatL-resistant dynamin mutants can prevent and even reverse proteinuria. Our data define a new role for cytoplasmic CatL (trigger) and dynamin (target) in the pathogenesis of glomerular proteinuria and open new potential avenues for pharmacological intervention of kidney disease.

Previous inhibitor studies suggested that CatL is involved in proteinuric kidney disease (4), and our current (Figure (Figure1D)1D) and previous work (3) has shown that CatL is upregulated in rodent models for nephropathy. Consistent with these findings, we observed an increase in levels of glomerular CatL mRNA in a number of human proteinuric diseases (Figure (Figure1A)1A) that correlated with a dramatic increase in the protein level in glomeruli (Figure (Figure1C).1C). Using knockout mice, we provide definitive evidence that CatL is essential to cause nephropathy in response to LPS in a mouse model (Figure (Figure1,1, D–F). Furthermore, we have shown that after LPS treatment, CatL appears in the cytoplasm, due to expression of the short form of the protein. Together, the data indicate that localization of CatL to the cytoplasm represents a key event in the induction of glomerular kidney disease. Consistent with this model, we show that dynamin, a cytoplasmic protein, is essential for kidney function and that it is cleaved by CatL after LPS treatment. Importantly, the dynamin p40 fragment generated by CatL cleavage functions as a dominant-negative inducer of proteinuria. Thus, the activity of the cytoplasmic CatL, in contrast to its lysosomal counterpart, seems to be specific and to yield a functional product (p40). These data argue that complete destruction of dynamin is not necessarily required to cause kidney failure.

Intriguingly, the CatL cleavage site is highly conserved among dynamin family members (Figure (Figure4A),4A), and its accessibility is suppressed by dynamin oligomerization. Moreover, cytoplasmic CatL targets only the GTP-bound form of dynamin, implying that only a portion of dynamin is cleaved in vivo. Our previous experiments indicate that dynamin:GTP is the active form of the enzyme (19, 26), so it is tempting to speculate that CatL functions to switch off dynamin much like the result of dynamin self-assembly. It remains to be seen whether this novel switch-off mechanism is ever used during normal cell physiology.

EM revealed 2 populations of actin in FPs of podocytes; one is the actin bundle running above the level of slit diaphragms, and the other is the cortical actin network located beneath the plasmalemma (27). Our data show that dynamin colocalizes with both of these populations (Figure (Figure3B).3B). It appears that FPs have the molecular makeup for constant morphological rearrangement in order to accommodate glomerular filtration. This membrane reshaping is most likely driven by rapid changes in the actin network (28), and our study suggests that it requires functional dynamin. On its C terminus, dynamin contains a proline-arginine rich domain (PRD) that binds directly to the Src homology 3 (SH3) domains of multiple proteins, some of which are actin-regulating or -binding proteins including profilin, Nck, Grb2, syndapin, intersectin, cortactin, mABP1, and tuba (reviewed in ref. 13). It is through these interactions that dynamin is thought to coordinate membrane remodeling and actin filament dynamics during endocytosis, cell morphogenesis, and cell migration. Despite these links between dynamin and actin, it is still unclear how exactly dynamin regulates actin dynamics. Our results identify podocytes, with their complex actin dynamics, as an appropriate cell type for investigating the interplay between dynamin’s role in endocytosis and its ability to regulate the actin cytoskeleton. Indeed, formation of a cortical actin cytoskeleton in cells expressing dynK44A or p40 or that have been treated with LPS (Figure (Figure6B)6B) could result from the inhibition of endocytosis, misregulation of actin dynamics, or both. While at present we have no direct evidence for a direct connection between actin and dynamin, addition of LPS does not inhibit endocytosis in cultured podocytes (Supplemental Figure 6), suggesting that loss of endocytosis per se is not sufficient to generate a cortical actin network. In agreement with this conclusion are experiments showing that expression of a known endocytosis inhibitor, dominant-negative auxilinH875Q (29), impaired endocytosis to the same extend as dynK44A (Supplemental Figure 6A), yet it did not alter actin morphology (Supplemental Figure 6B). In addition, nondifferentiated podocytes contained predominantly cortical actin (Supplemental Figure 6B), yet they exhibited WT levels of endocytosis (Supplemental Figure 6A). In sum, there seems to be no correlation between levels of endocytosis and actin dynamics in podocytes, raising the possibility that dynamin mutants might primarily act on podocyte actin dynamics. This conclusion is also in line with the observation that CatL reduced endogenous dynamin by only 30% (Figure (Figure3D),3D), possibly maintaining dynamin’s role in endocytosis. Regardless of these observations, dynamin is clearly present on clathrin-coated pits in podocytes (Figure (Figure3A),3A), and changes in endocytosis have been implicated in some forms of podocyte failure (30). Clearly, more work is needed to define the exact role(s) of dynamin in podocytes.

Proteinuria was resolved by expression of dynR725A, dynL356Q, and to some degree dynWT. While our study shows that dynamin is efficiently delivered and expressed in podocytes, it is unlikely that every podocyte received dynamin. We propose that damaged podocytes may be particularly amenable to uptake of DNA presented in polymers (8, 31). Alternatively, it is conceivable that the effects of gene-delivered dynamin has multiple effects in podocytes. For example, it seems possible that restoration of podocyte actin has a salutary effect on the slit diaphragm function. Finally, gene-delivered dynamin in podocytes may have a non–cell-autonomous effect on other resident glomerular cells such as glomerular endothelial cells. Whatever the precise mechanism, the use of dynamin mutants as a treatment for human kidney disease is an attractive subject for future experiments.

Methods

Cells, antibodies, reagents, and standard techniques.

Mouse podocyte cell lines were grown as described previously (32). Dynamin antibodies included anti-dynamin (hudy 1) from Upstate Technology; mouse anti-dyn1 5402 from Chemicon; VAM-SV041 from Stressgen. Two rabbit antisera against CatL were used as described previously (8, 33). CatL–/– fibroblasts were maintained as described previously (34). Stable CatL-knockdown cell lines were generated with a vector-based siRNA directed against CatL (target sequence 5′-GTGGACTGTTCTCACGCT-3′). Quantitative PCR was performed on an Applied Biosystems 7300 Real-Time PCR System. Fold expression changes were calculated using the comparative CT method for relative quantitation with the equation 2–ΔΔCT. Protein expression levels for dynamin and CatL were calculated using results of densitometric analysis from 7 independent experiments with Kodak 1D Image Analysis software. Statistical significance was assessed with the unpaired Student’s t test with Welch’s correction. P less than 0.05 was considered statistically significant. Transfections with CatL constructs were performed using Lipofectamine 2000 (Invitrogen). Immunocytochemical analysis of cultured podocytes was performed as described previously (3). BIOMOL CV-CatL/B activity kit was utilized as described in the manufacturer’s instructions. The fluorophore cresyl violet [CV-(FR)2] substrate becomes florescent after CatL/B cleavage of the attached Phe-Arg groups. This substrate easily penetrates the cell membrane and the membranes of the internal cellular organelles, enabling the detection of cathepsin activity within living podocytes. Immunoperoxidase labeling of human tissue was done on formalin-fixed kidney biopsy samples embedded in paraffin. Transmission electron microscopy and immunoelectron microscopy were performed as described previously (35). Subcellular fractionation was performed as described (36).

Animals and treatments.

All animal studies were approved by the MGH Subcommittee for Research Animal Care. C57BL/6 mice were obtained from The Jackson Laboratory. CatL–/– mice were on a pure C57BL/6 background (10). The mouse model LPS-induced proteinuria was utilized as previously described (3). The rat PAN nephrosis model was induced as described (37).

Patients and quantitative glomerular rt-PCR.

Microdissected glomeruli from patients with proteinuric diseases and from control subjects were analyzed. Biopsies were obtained from patients and donors after informed consent and with approval of the local ethical committees. For control biopsies, renal tissue was derived from pretransplantation kidney biopsies during cold ischemia time from 7 living and 1 cadaveric donor (n = 8) (38). Statistical analysis was performed using the Kruskal-Wallis test and Mann-Whitney U test. P less than 0.05 was considered statistically significant.

Processing of dynamin by CatL in vitro.

Recombinant dynamin was purified as described previously (39). One microgram of dynamin (10 pmol) was diluted in buffer containing 200 mM NaCl, 10 mM HEPES pH 7.0, 2 mM EGTA, 1 mM MgCl2, and 1 mM DTT. When indicated, 200 μM of GTP or 1 mM of GTP[Upsilon]S was added, and dynamin was allowed to bind nucleotides for 10 minutes on ice. The reaction was initiated by addition of 0.5 μl of purified CatL (specific activity 4.13 U/mg of protein from Sigma-Aldrich), and samples were placed at 37°C in the water bath for 10 minutes. Total assay volume was 20 μl. The reaction was terminated with addition of E-64d inhibitor (Sigma-Aldrich) and sample buffer. For Western blot analysis, 5 μl of the samples was run on 10% SDS-PAGE. When CatB (specific activity 3.00 U/mg of protein from Sigma-Aldrich) or recombinant human furin (from R&D Systems) were used, 2 μl of the enzymes were added in the assay.

Adenoviral infections of cultured podocytes.

Podocytes were grown to 70% confluency. Cells were washed twice with 1× PBS and infected with 1.2 ml of serum-free DMEM medium containing 100 μl transactivator virus and 100 μl virus expressing dyn1 or dyn2. After 2 hours of infection at 37°C, medium containing virus was replaced with full DMEM. If cells were treated with LPS or PAN, 50 μg/ml of LPS or 50 μg/ml PAN was added at this point. Eighteen to 24 hours after infection, cells were detached using trypsin and either processed for subcellular fractionation or tested in the motility assays as described in ref. 3. When indicated, 20 μM of Z-FF-FMK CatL specific inhibitor (Calbiochem) was added simultaneously with LPS.

Kidney extracts.

Four mouse kidneys were homogenized in buffer containing 20 mM HEPES pH 7.5, 100 mM NaCl, 1 mM MgCl2, 1 mM PMSF, proteinase inhibitors, calpain inhibitor (Calbiochem), and E-64d using Dounce homogenizer. Subsequently, cytosol was centrifuged for 10 minutes at 4,600 g. Proteins were solubilized by 1% Triton X, 1 hour at 4°C, before it was spun at 70,000 g for 1 hour.

In vivo gene delivery.

CatL plasmids encoding short and long CatL (5), dyn1 plasmids (all pcDNA), or p2.5 podocin-promoter driven (22) were introduced into mice (n >10, each construct) using the TransIT in vivo gene delivery system according to the manufacturer’s instructions (Mirus). Proteinuria was assessed using Multistix 8 SG strips (Bayer) (data not shown) and the Bradford protein assay (Sigma-Aldrich).

Supplementary Material

Supplemental data:

Acknowledgments

This work was supported by the American Society for Nephrology (to S. Sever and J. Reiser) and the NIH (R01 DK64787 to S. Sever and R01 DK073495 to J. Reiser). J. Reiser was also supported by the KMD foundation. M.M. Altintas was supported by an NIH training grant and T32DK007540, and C.C. Möller by a Deutscher Akademischer Austausch Dienst (DAAD) Predoctoral Scholarship. The authors are grateful for the analysis of CatL cleavage sites by Thomas Reinheckel and Tobias Lohmueller, University of Freiburg. The authors are indebted to Johannes Walter for critically reading the manuscript. The fluorescence and electron microscopy work was performed in the Microscopy Core facility of the MGH Program in Membrane Biology, supported by an NIH Program Project grant (DK38452), the NIH Boston Area Diabetes and Endocrinology Research Center (DK57521), and the NIH Center for the Study of Inflammatory Bowel Disease (DK43341). We thank all members of the European Renal cDNA Bank and their patients for their support (for participating centers at the time of the study see ref. 38).

Footnotes

Nonstandard abbreviations used: CatL, cathepsin L; FP, foot process; PAN, puromycin aminonucleoside.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J. Clin. Invest. 117:2095–2104 (2007). doi:10.1172/JCI32022

Mehmet M. Altintas, Sharif R. Nankoe, and Clemens C. Möller contributed equally to this work.

See the related Commentary beginning on page 2079.

References

1. Zandi-Nejad K., Eddy A.A., Glassock R.J., Brenner B.M. Why is proteinuria an ominous biomarker of progressive kidney disease? . Kidney Int. Suppl. 2004;66:S76–S89. [PubMed]
2. Tryggvason K., Patrakka J., Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. N. Engl. J. Med. 2006;354:1387–1401. [PubMed]
3. Reiser J., et al. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin l and alpha3 integrin. J. Biol. Chem. 2004;279:34827–34832. [PubMed]
4. Baricos W.H., O’Connor S.E., Cortez S.L., Wu L.T., Shah S.V. The cysteine proteinase inhibitor, E-64, reduces proteinuria in an experimental model of glomerulonephritis. Biochem. Biophys. Res. Commun. 1988;155:1318–1323. [PubMed]
5. Goulet B., et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol. Cell. 2004;14:207–219. [PubMed]
6. Cohen C.D., Kretzler M. Gene-expression analysis of microdissected renal biopsies. Methods Mol. Med. 2003;86:285–293. [PubMed]
7. Olbricht C.J., Cannon J.K., Tisher C.C. Cathepsin B and L in nephron segments of rats with puromycin aminonucleoside nephrosis. Kidney Int. 1987;32:354–361. [PubMed]
8. Ahn K., et al. An alternate targeting pathway for procathepsin L in mouse fibroblasts. Traffic. 2002;3:147–159. [PubMed]
9. Asanuma K., Shirato I., Ishidoh K., Kominami E., Tomino Y. Selective modulation of the secretion of proteinases and their inhibitors by growth factors in cultured differentiated podocytes. Kidney Int. 2002;62:822–831. [PubMed]
10. Nakagawa T., et al. Cathepsin L: critical role in Ii degradation and CD4 T cell selection in the thymus. Science. 1998;280:450–453. [PubMed]
11. Lohmuller T., et al. Toward computer-based cleavage site prediction of cysteine endopeptidases. Biol. Chem. 2003;384:899–909. [PubMed]
12. Kirchhausen T. Three ways to make a vesicle. Nat. Rev. Mol. Cell Biol. 2000;1:187–198. [PubMed]
13. Schafer D.A. Regulating actin dynamics at membranes: a focus on dynamin. Traffic. 2004;5:463–469. [PubMed]
14. Inokuchi S., et al. Re-evaluation of foot process effacement in acute puromycin aminonucleoside nephrosis. Kidney Int. 1996;50:1278–1287. [PubMed]
15. Mayer G., Boileau G., Bendayan M. Furin interacts with proMT1-MMP and integrin alphaV at specialized domains of renal cell plasma membrane. J. Cell Sci. 2003;116:1763–1773. [PubMed]
16. Moller C.C., et al. Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J. Am. Soc. Nephrol. 2007;18:29–36. [PubMed]
17. Muhlberg A.B., Warnock D.E., Schmid S.L. Domain structure and intramolecular regulation of dynamin GTPase. EMBO J. 1997;16:6676–6683. [PubMed]
18. Akagi Y., et al. Transcriptional activation of a hybrid promoter composed of cytomegalovirus enhancer and beta-actin/beta-globin gene in glomerular epithelial cells in vivo. Kidney Int. 1997;51:1265–1269. [PubMed]
19. Sever S., Muhlberg A.B., Schmid S.L. Impairment of dynamin’s GAP domain stimulates receptor-mediated endocytosis. Nature. 1999;398:481–486. [PubMed]
20. Zhang P., Hinshaw J.E. Three-dimensional reconstruction of dynamin in the constricted state. Nat. Cell Biol. 2001;3:922–926. [PubMed]
21. Fish K.N., Schmid S.L., Damke H. Evidence that dynamin-2 functions as signal-transducing GTPase. J. Cell Biol. 2000;150:145–154. [PMC free article] [PubMed]
22. Moeller M.J., Sanden S.K., Soofi A., Wiggins R.C., Holzman L.B. Podocyte-specific expression of cre recombinase in transgenic mice. Genesis. 2003;35:39–42. [PubMed]
23. Verma R., et al. Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization. J. Clin. Invest. 2006;116:1346–1359. doi: 10.1172/JCI27414. [PubMed] [Cross Ref]
24. Damke H., Freundlieb S., Gossen M., Bujard H., Schmid S.L. Tightly regulated and inducible expression of a dominant interfering dynamin mutant in stably transformed HeLa cells. Methods Enzym. 1995;257:209–221.
25. Reiser J., et al. Regulation of mouse podocyte process dynamics by protein tyrosine phosphatases. Kidney Int. 2000;57:2035–2042. [PubMed]
26. Sever S., Damke H., Schmid S.L. Dynamin:GTP controls the formation of constricted coated pits, the rate limiting step in clathrin-mediated endocytosis. J. Cell Biol. 2000;150:1137–1148. [PMC free article] [PubMed]
27. Ichimura K., Kurihara H., Sakai T. Actin filament organization of foot processes in rat podocytes. J. Histochem. Cytochem. 2003;51:1589–1600. [PubMed]
28. Moeller M.J., Holzman L.B. Imaging podocyte dynamics. Nephron Exp. Nephrol. 2006;103:e69–e74. [PubMed]
29. Sever S., et al. Physical and functional connection between auxilin and dynamin during endocytosis. EMBO J. 2006;25:4163–4174. [PubMed]
30. Kim J.M., et al. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science. 2003;300:1298–1300. [PubMed]
31. Eyre J., et al. Statin-sensitive endocytosis of albumin by glomerular podocytes. Am. J. Physiol. Renal Physiol. 2006;292:F674–F681. [PubMed]
32. Mundel P., et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp. Cell Res. 1997;236:248–258. [PubMed]
33. Ishidoh K., Kominami E. Multi-step processing of procathepsin L in vitro. FEBS Lett. 1994;352:281–284. [PubMed]
34. Hsieh C.S., deRoos P., Honey K., Beers C., Rudensky A.Y. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation. J. Immunol. 2002;168:2618–2625. [PubMed]
35. Regele H.M., et al. Glomerular expression of dystroglycans is reduced in minimal change nephrosis but not in focal segmental glomerulosclerosis. J. Am. Soc. Nephrol. 2000;11:403–412. [PubMed]
36. Damke H., Baba T., Warnock D.E., Schmid S.L. Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J. Cell Biol. 1994;127:915–934. [PMC free article] [PubMed]
37. Kim S.W., et al. Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats. Am. J. Physiol. Renal Physiol. 2004;286:F922–F935. [PubMed]
38. Schmid H., et al. Gene expression profiles of podocyte-associated molecules as diagnostic markers in acquired proteinuric diseases. J. Am. Soc. Nephrol. 2003;14:2958–2966. [PubMed]
39. Damke H., et al. Expression, purification, and functional assays for self-association of dynamin-1. Methods Enzymol. 2001;329:447–457. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation